摘要
新生血管是糖尿病视网膜病变发展及预后的关键。目前已报道多种抗新生血管药物，其中部分药物如糖皮质激素、血管内皮生长因子抑制剂等已广泛应用于临床，可不同程度地抑制新生血管生成。而其他药物仍处于动物或临床试验，除血管生长抑制因子、胰岛素样生长因子结合蛋白-3可直接抑制新生血管外，富亮氨酸α-2糖蛋白-1、连接蛋白Shc均参与到新生血管生成过程，可成为抗新生血管新的治疗靶点。
Angiogenesis is the key to the progress and prognosis of diabetic retinopathy （DR）. So far, published studies have shown lots of antiangiogenic drugs. Some of these drugs, such as glucocortieoid and vascular endothelial growth factor inhibitors, has been widely applied in clinic, inhibiting neovascular- ization in different degrees. And the others has been still in animal or clinical trials. Besides insulin-like growth factor binding protein 3 and angiostatin controlling angiogenesis directly, leucine-rich alpha-2-glyco- protein 1 and connexin Shc could participate in the process of neovascularization, to become the new thera-peutic targets of antiangiogensis.
出处
《国际眼科纵览》
2015年第4期274-277,共4页
International Review of Ophthalmology
基金
长沙市科技计划项目（K1203037-31）
爱尔眼科医院集团科研基金项目（AF141201）
